Hims & Hers just posted strong earnings. The stock still got punched in the face. That’s not a contradiction — it’s the whole story.

HIMS is one of the market’s most polarizing growth names right now. Bulls see a profitable DTC healthcare machine with a loyal subscriber base and a massive runway. Bears see a company that flirted with regulatory fire, leaned too hard into weight-loss hype, and now trades like a momentum stock that lost its momentum. The chart agrees with the bears. The business, less so.

The bull case: this is a real company now, not a vibe

Strip out the noise and the earnings were clean. Revenue nearly doubled year over year. Full-year sales hit roughly $1.5B. Net income swung solidly positive. Free cash flow crossed $190M. That’s not a startup anymore — that’s an operating business printing cash.

The core engine still works. Subscribers grew about 45% year over year. ARPU jumped. People aren’t just signing up for hair loss and ghosting — they’re stacking treatments and staying put. That’s the quiet flex in HIMS’ model: it’s a bundle business disguised as telehealth.

Bulls also point out something the selloff ignores. The GLP-1 mess didn’t break the company. It exposed how little HIMS actually needs weight loss to grow. Sexual health, dermatology, mental health — those lines are scaling without legal threats attached. If management dials back the cowboy behavior and sticks to approved lanes, growth doesn’t fall apart. It just looks less flashy.

And yes, valuation compressed hard. After the drop, HIMS isn’t priced like a perfect rocket ship anymore. For long-term investors, that matters.

The bear case: regulatory gravity always wins

Now the bad part. HIMS poked the FDA bear — and got mauled.

The compounded semaglutide rollout was aggressive, public, and sloppy. It triggered DOJ referrals, lawsuits from Novo Nordisk, and a very clear message from regulators: stop. The stock lost about a quarter of its value because the market realized something uncomfortable — management chased hype and assumed forgiveness would come later.

Bears aren’t arguing that weight loss was the whole business. They’re arguing it was the multiple. Investors were pricing HIMS like it had cracked the GLP-1 code. It hasn’t. And it won’t, at least not cheaply or quickly.

Margins are another pressure point. Gross margin slid as the company pushed into new categories and spent more to grow. That’s fine when the stock’s ripping. It’s less fine when trust gets dented and the market demands discipline.

Then there’s the simple issue of credibility. Growth stocks live and die on it. One regulatory faceplant doesn’t kill a company. But it does reset how much optimism the market is willing to front-run.

What the chart says: damage done, but not fatal

Technically, HIMS looks rough. The post-earnings selloff broke the 50-day moving average with volume — never a great look. Momentum flipped fast, and dip-buyers didn’t step in immediately. That’s distribution, not panic.

There’s a clear support zone forming in the mid-to-high teens, where buyers finally slowed the fall. Lose that, and the stock probably bleeds toward the low teens as valuation re-rates again. Hold it, and you’re likely looking at a long, boring base.

Upside isn’t imminent. The prior $25–$30 range is now heavy resistance. Anyone who bought the hype will be happy to sell into strength. That caps rallies for a while.

Translation: the chart says this isn’t a “buy the dip and brag tomorrow” setup. It’s a “wait and see if management earns trust back” setup.

The bottom line

HIMS didn’t implode. It stumbled — loudly — at the exact moment the market stopped rewarding mistakes. The bull case is still intact, but it’s slower, less sexy, and more execution-dependent. The bear case owns the short term, because credibility and momentum both took hits.

If management tightens up and growth keeps compounding, this selloff will look like a gift in hindsight. If they chase the next shiny thing to juice the narrative, the market won’t be forgiving twice.

The chart is neutral-to-bearish. The business is solid. The stock needs time. And patience, right now, is the actual edge.

#HimsAndHersRealityCheck #StockMarketTrust #BusinessCredibility #EarningsVsExpectations #GrowthWithoutGimmicks #InvestingWisdom #MarketBehaviorMatters #LongTermInvesting #CorporateResponsibility #FinancialTransparency